Nasdaq Breakout Idea (NMTC) Is Low Float Past Champ With 5 Important Potential Catalysts

Let's break down some stats real quick. Nasdaq Breakout Idea (NMTC) Is Low Float Past Champ With 5 Important Potential Catalysts  July 10th Dear Reader, Let's break down some stats real quick. My last alert from this past Wednesday turned into a strong intraday runner. Making a move of approximately 12%, it was one of the few bright spots during a short holiday week which saw the Dow and Nasdaq Markets both take a hit. But now it's time to pivot to a Nasdaq past champ. Here's the brass tacks. This past champ has been a doozy on multiple occasions. Most recently, this explosive profile erupted during a 3-day surge that saw it run approximately 28%. Before that? This profile accumulated approximately 188% combined in short term runs over 2 previous alerts. Even better, it popped approximately $1.00+ on the way to donning the champ's crown both of those times. As a low float idea (fewer than 15Mn shares), this Nasdaq idea needs to be at the top of your watch-list Monday. Also, factor in that it closed above [4 key lines]( of potential support Friday in a bullish short term manner. And with the company operating within a [global market for neurostimulation devices]( that is expected to reach $6Bn, now could be the perfect time to get them on radar. Those are only some of the reasons why this Nasdaq 3X past champ needs immediate attention: *NeuroOne Medical Technologies Corporation (NMTC)* NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. And right now, NMTC has 5 potential catalysts to immerse yourself in: No. 1 - A Low Float Provides Volatility Potential Daily No. 2 - Company Submits 510(k) Application To FDA For OneRF™ Ablation System No. 3 - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch No. 4 - Milestone "Firsts" For The Company's Game-Changing Evo® sEEG Electrode No. 5 - Exciting Patent News Adds To Company's Growing Portfolio But more on those in a second... Evo® Cortical Electrode Cortical or subdural electrodes are used in electrocorticography (ECoG) or intracranial electroencephalography (iEEG) surgeries to monitor, record and stimulate the surface of the brain for up to 30 days. The company's Evo cortical electrode portfolio consists of various contact configurations of strip and grid electrodes. (Rx only) The Evo Advantage (2) Decreased Immunological Response - The Evo Electrode is over 7 times thinner than a silicone electrode. The flexibility and reduced volume should reduce pain and edema. The Evo’s polyimide substrate has properties like increased flexibility, reduced volume, and decreased immunological response, which should reduce signal artifacts. Single Tail Design - The single thin tail design allows the implanted electrode tail to be tunneled through one incision which should reduce infection risk and procedure time. Reduced Cable Management - A disposable cable assembly is sent with each Evo Electrode as an electrode kit, removing the need to source the correct cables for each electrode being used in surgery. Also, hospital resources are freed from the management of sterilizing and storing individual electrode cable assemblies. How NeuroOne's Thin Film Electrode Technology is Different In comparison to currently available technologies, our electrodes are manufactured with polyimide thin film. Our electrodes are designed to reduce trauma to the brain by allowing a less invasive implant due to the flexibility, thinness and reduced weight of the electrode. Furthermore, the potential to significantly increase the resolution of brain recordings may enable the usage of powerful computing techniques, such as machine learning and artificial intelligence. Caution: US Federal law restricts this device to sell by or on the order of a physician Two FDA-Cleared Devices and Counting (3) Are you beginning to understand that NeuroOne is not just “another” MedTech company? In fact, their Evo Cortical and sEEG Electrodes are both FDA approved! What they are doing right now has incredible implications for the future of the medical industry. So much so that the technologies below could be commonplace and in wide use across the globe. [Read more from the company presentation here.]( ----- And as I mentioned previously, NMTC has 5 must-see potential catalysts right now: No. 1 NMTC Potential Catalyst - A Low Float Provides Volatility Potential Daily According to the [Yahoo Finance]( website, NMTC has a low float. The website reports this profile to have approximately 14.91Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive 2023 company news help provide a near term spark? ----- No. 2 NMTC Potential Catalyst - Company Submits 510(k) Application To FDA For OneRF™ Ablation System NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the added benefit of temperature control EDEN PRAIRIE, Minn., June 12, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today its submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF™ Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency (RF) generator. If cleared by the FDA, NeuroOne’s OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery. ... [Read the full article here.]( ----- No. 3 NMTC Potential Catalyst - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes Evo sEEGs complementary to Zimmer Biomet’s robotic neurosurgery platform; strong market opp. for paired technologies EDEN PRAIRIE, Minn., May 02, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the commercial launch of the Evo® sEEG electrode product line in the United States. Zimmer Biomet holds exclusive worldwide distribution rights to NeuroOne’s Evo Cortical and sEEG product lines, and the Evo product line is expected to utilize Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures. ... [Read the full article here.]( ----- No. 4 NMTC Potential Catalyst - Milestone "Firsts" For The Company's Game-Changing Evo® sEEG Electrode In recent months, the company has made a few milestone announcements in regards to firsts for the Evo® sEEG Electrode being put to use. Here's what you need to know: NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery Evo sEEG electrode used with Zimmer Biomet’s ROSA One® Brain during procedure at Cleveland Clinic EDEN PRAIRIE, Minn., May 17, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo® sEEG electrode in robotic neurosurgery. Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne’s Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures. Dave Rosa, CEO of NeuroOne, commented, “This clinical case utilizing our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne’s partnership with Zimmer Biomet. Now that Zimmer Biomet has commenced U.S. distribution of our Evo sEEG electrodes, this case study confirms the synergistic use of our product with Zimmer Biomet’s robotics platform which was the foundation of our interest to partner with Zimmer Biomet.” ... [Read the full article here.]( And just prior to that announcement: NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic Evo sEEG electrodes used for brain mapping in epilepsy surgery EDEN PRAIRIE, Minn., May 10, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its first clinical case using the Evo® sEEG electrode was performed by Dr. Jamie Van Gompel at Mayo Clinic. Using a non-robotic stereotactic frame system, Evo electrodes were implanted successfully and met the Company’s product performance objectives. Dave Rosa, CEO of NeuroOne, commented, “We would like to thank Dr. Van Gompel and his surgical team at Mayo for this 'first in the world' opp. We are ecstatic with the initial performance of our Evo sEEG electrodes which confirmed the results of many years of testing on the device. While we previously used the device intraoperatively, this was the first clinical case that was cleared by the FDA for less than 30 day use. We look forward to continued success with the launch of the technology as we continue the roll out of the technology through our distribution partner, Zimmer Biomet.” ... [Read the full article here.]( ----- No. 5 NMTC Potential Catalyst - Exciting Patent News Adds To Company's Growing Portfolio NeuroOne® Awarded U.S. Patent Covering Novel and Proprietary Thin Film Electrode Platform New patent adds value to NeuroOne's growing patent portfolio in the U.S. and abroad EDEN PRAIRIE, Minn., March 7, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces it has been awarded a patent from the United States Patent and Trademark Office relating to its novel and proprietary electrode technology. ... Dave Rosa, CEO of NeuroOne, comments, "NeuroOne is committed to protecting our groundbreaking electrode technology with respect to device claims and proprietary manufacturing processes. With a plethora of patent applications both in the U.S. and overseas relating to procedures in epilepsy, Parkinson's disease, chronic back pain and drug/gene delivery, we believe the Company is well positioned to impact a number of key neurological conditions with patent-protected novel electrodes. We look forward to continued success with our patent applications." [Read the full article here.]( ----- NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately No. 1 - A Low Float Provides Volatility Potential Daily No. 2 - Company Submits 510(k) Application To FDA For OneRF™ Ablation System No. 3 - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch No. 4 - Milestone "Firsts" For The Company's Game-Changing Evo® sEEG Electrode No. 5 - Exciting Patent News Adds To Company's Growing Portfolio ----- Coverage is officially reinitiated on NMTC. When time permits, do this: Get NMTC on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer [Source 1]( [Source 2]( [Source 3]( (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 8/7/22 and ending on 8/9/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 11/20/22 and ending on 11/21/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 3/6/23 and ending on 3/7/23 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 7/9/23 and ending on 7/11/23 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). To date we have been compensated a total of sixty-two thousand five hundred USD via bank wire transfer to disseminate information about (NMTC). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 07/07/2023 and ending on 07/10/2023 to publicly disseminate information about (NMTC:US) via digital communications. We have been paid an additional forty eight thousand dollars USD. To date we have been paid four hundred sixty five thousand dollars USD to disseminate information about (NMTC:US) via digital communications. We own zero shares of (NMTC:US). [( Fierce | 401 W. Atlantic Ave., Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net